High-Dose Lanreotide in the Treatment of Poorly Differentiated Pancreatic Neuroendocrine Carcinoma: A Case Report

Publisher： Karger

E-ISSN： 1662-6575|7|1|155-163

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.7, Iss.1, 2014-03, pp. : 155-163

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma

By  

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, Vol. 22, Iss. 8, 2015-08 ,pp. : 623-627

John Wiley & Sons Inc

Access to resources Recommend Favorite

Targeted Therapies Provide Treatment Options for Poorly Differentiated Pancreatic Neuroendocrine Carcinomas

By  

Oncology, Vol. 92, Iss. 3, 2016-11 ,pp. : 170-172

Karger

Access to resources Recommend Favorite

Long-Term Disease Control of a Pancreatic Neuroendocrine Tumor with Lanreotide Autogel®: A Case Report

By  

Case Reports in Oncology, Vol. 7, Iss. 3, 2014-09 ,pp. : 673-680

Karger

Access to resources Recommend Favorite

A Case of Poorly Differentiated Large-Cell Neuroendocrine Carcinoma of the Cecum: A Rare Malignancy, with Review of the Literature

By  

Case Reports in Oncology, Vol. 9, Iss. 3, 2016-12 ,pp. : 847-853

Karger

Access to resources Recommend Favorite

Epidermal Growth Factor Mutation as a Diagnostic and Therapeutic Target in Metastatic Poorly Differentiated Thyroid Carcinoma: A Case Report and Review of the Literature

By  

Case Reports in Oncology, Vol. 7, Iss. 2, 2014-06 ,pp. : 393-400

Karger

Access to resources Recommend Favorite